About the Medigreen Biotechnology Corp.   Medigreen Biotechnology Corporation, founded on April 10th, 2002, is focusing on the development of botanical new drugs and is established by domestic and overseas outstanding enterprises and entrepreneurs, in accordance with the government’s promotion policy, to develop the Chinese Traditional Medicine industry. The major stockholders of Medigreen include Medigen Biotechnology Corp., SunTen Phytotech Co., Ltd. and YFY Biotech Management Company, etc. Since the foundation, based on the mission of“contribution to the human health”and on the main principle of the immunologic system, Medigreen has been worked on the R & D of new botanical drugs on “cancer adjuvant”,“anti-ulcer”and“respiratory tract diseases”. Medigreen develops diverse functional products and ingredients on the base of the Traditional Chinese Medicine theory, the concept of“medicine and food from the same source”, and the efficacy examination of biotechnology followed the new drug development process to contribute to the human health and to guarantee the persistent progress of the enterprise during the new drug development.   BUSINESS OBJECTIVE   ．eveloping functional foods and new drugs according to the standards of well-developed countries and creating global business. ．Pay equal attention to the R & D activities and business activities. Trying to create the greatest profit of the stockholders and to fulfill the social responsibilities during the new drug development.   BUSINESS MODEL   The business model of Medigreen is following the new drug development process to specialize in the development of botanical products, patent application, and protection of intellectual property rights; It means from the functional foods, development of health food advancing toward the goal of new drugs development; the usage experience of each level’s commodities and the market information as the reference for the new drugs development, as well as the platform and standard of development of new drugs serve for increasing the value of the product. Based on the principle of specialized labor division, combining with the specialists of different areas to be cooperation partners; using different resources of the production, official, academic and research areas, reducing the R & D costs and risks, increasing the development efficiency, and then entering the international market of the development of new drugs through the common development networks.